• Restructure
  • About Purdue
    • Ethics and Compliance
    • Locations & Operations
    • Public Policies
  • News & Media
    • New Media Resources
    • Perspectives
    • Media Contacts
  • Careers at Purdue
    • What We Offer You
    • How to Apply
  • Contact Us
Purdue Pharma
  • Healthcare Professionals
    • Purdue Products
    • Patient Savings
    • Ask Purdue Medical
    • Responsible Use of Opioids
    • Clinical Trials
  • Patients & Caregivers
    • Medicines From Purdue
    • Cost Savings
    • Ask Purdue Medical
    • Responsible Use of Opioids
    • Expanded Access Program
  • Addressing the Crisis
    • Public Policies
    • Strong Track Record
    • Ongoing Efforts
    • What We’re Doing Now
    • Perspectives
  • Partnering
  • Corporate Social Responsibility
    • Grants & Giving
Select Page

Purdue Pharma Announces Landmark Agreement with Oklahoma to Advance the Treatment of Addiction

Mar 22, 2019 | News

News and Media Settlement will establish national center for addiction studies and treatment in Tulsa; Sackler family announces voluntary contribution to support national center STAMFORD, Conn., March 26, 2019 — Purdue Pharma L.P. today announced that it has...

FDA Grants Purdue Pharma’s Nalmefene HCl Injection Fast Track Designation for the Emergency Treatment of Known or Suspected Opioid Overdose

Mar 13, 2019 | News

News and Media Committed to advancing solutions to the opioid public health crisis, Purdue will not profit from nalmefene HCl STAMFORD, Conn., March 13, 2019 — Purdue Pharma L.P. today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track...

Recent Posts

  • Purdue Pharma Announces Agreement in Principle on Landmark Opioid Litigation Settlement
  • The Prescription Drug Safety Network Significantly Expands Its Reach in Year 2 and Reports an Average 48% Knowledge Gain Nationwide
  • Purdue Pharma L.P. and the National Center for Wellness & Recovery at Oklahoma State University Announce Collaboration Around Research to Address the Opioid Addiction Crisis
  • Julie Ducharme, BPharm, MSc, PhD Named Vice President and Chief Scientific Officer of Purdue Pharma L.P.
  • Purdue Pharma Presents Considerations in Opioid Comparator Selection at the College on Problems of Drug Dependence Annual Scientific Meeting

Archives

  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • October 2018
  • September 2018
  • August 2018
  • February 2018
  • January 2018

Categories

  • News
Purdue, as used in this site, refers to Purdue Pharma L.P. and its subsidiaries, which include Avrio Health L.P., Imbrium Therapeutics L.P., Adlon Therapeutics L.P. and Greenfield BioVentures L.P., Rhodes Pharmaceuticals L.P., Rhodes Technologies, Purdue Pharmaceuticals L.P., and Purdue Pharma Manufacturing L.P.